CDCA1-derived peptide and vaccine containing same

A method of treating a cancer expressing CDCA1 and HLA-A01 in a subject having a homozygous HLA-A01 in need of the cancer treatment, wherein the method comprises the steps below:

• (i) measuring the level of CDCA1 expression in a biological sample collected from the diseased site of a subject with cancer;
• (ii) identifying a subject with CDCA1-overexpressing cancer based on the CDCA1 expression level measured in (i);
• and
• (iii) administering to the subject with CDCA1-overexpressing cancer as compared to normal control at least one ingredient selected from the group consisting of (a) to (e) below:
• (a) one or more types of peptides;
• (b) one or more types of polynucleotides encoding one or more types of peptides in an expressible form;
• (c) an antigen-presenting cell (APC) that presents on its cell surface a complex of a peptide and an HLA;
• (d) an exosome that presents on its cell surface a complex of a peptide;
• and
• (e) a CTL that targets a peptide;
• wherein the peptide or each of the one or more types of peptides is a CDCA1-derived HLA-A01-restricted peptide having cytotoxic T cell (CTL)-inducing ability, which consists of the amino acid sequence selected from the group consisting of SEQ ID NOs:
• 1, 8, 10, 13, 25, 33 to 35 and 37.

A method of inducing an immune response against cancer in a subject having a homozygous HLA-A01 in need of the cancer treatment, which comprises administering to the subject at least one ingredient selected from the group consisting of (a) to (e) below:

• (a) one or more types of peptides;
• (b) one or more types of polynucleotides encoding one or more types of peptides in an expressible form;
• (c) an antigen-presenting cell (APC) that presents on its cell surface a complex of a peptide and an HLA;
• (d) an exosome that presents on its cell surface a complex of a peptide;
• and
• (e) a CTL that targets a peptide;
• wherein the peptide or each of the one or more types of peptides is a CDCA1-derived HLA-A01-restricted peptide having cytotoxic T cell (CTL)-inducing ability, which consists of the amino acid sequence selected from the group consisting of SEQ ID NOs:
• 1, 8, 10, 13, 25, 33 to 35 and 37.